Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.53 Analyst target: $3.33 Upside: 117.84%
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
See the full interactive analysis & chart →Informational only — not investment advice.